There is considerable controversy about the classification acid nomenc
lature of somatostatin receptors. To date, five distinct receptor gene
s have been cloned and named chronologically according to their respec
tive publication dates, but two were unfortunately given the same appe
llation (SSTR(4)). Consensually, a nomenclature for the recombinant re
ceptors has been agreed according to IUPHAR guidelines (sst(1), sst(2)
, sst(3), sst(4) and sst(5)). However, a more informative classificati
on is to be preferred for the future, employing all classification cri
teria in an integrated scheme. It is already apparent that the five re
combinant receptors fall into two classes or groups, on the basis of n
ot only structure but also pharmacological characteristics. One class
(already referred to by some as SRIF(1)) appears to comprise sst(2), s
st(3) and sst(5) receptor subtypes. The other class (SRIF(2)) appears
to comprise the other two recombinant receptor subtypes (sst(1) and ss
t(4)). This promising approach is discussed but it is acknowledged tha
t much more data from endogenous receptors in whole tissues are needed
before further recommendations on somatostatin receptor nomenclature
can be made.